Top

Current Treatment Options in Gastroenterology

Published in:

01-06-2019 | Obesity | Endoscopy (P Siersema, Section Editor)

Endoscopic Bariatric Therapies: Intragastric Balloons, Tissue Apposition, and Aspiration Therapy

Authors: Joshua A. Turkeltaub, MD, Steven A. Edmundowicz, MD

Published in: Current Treatment Options in Gastroenterology | Issue 2/2019

Abstract

Purpose of review

Endoscopic bariatric therapies (EBTs) have been identified as a group of procedures that can bridge the treatment gap between bariatric surgical procedures and non-procedural treatments such as pharmacotherapy and lifestyle therapy. We will review the recent progress that has been made in this important area in the past several years.

Recent findings

Traditional intragastric balloons (IGB) that are both placed and removed endoscopically have been the fixture of IGB therapy. They have been shown to be safe and effective, when kept in place for 6 months. Newer IGBs, both currently FDA approved and those in clinical trials, have unique features. The Obalon gastric balloon system is gas filled and does not require endoscopy for placement. The Elipse balloon system that is in clinical trials neither requires endoscopy for placement nor removal. The Spatz3 balloon is in clinical trials and can be adjusted endoscopically by adding or subtracting volume to titrate balloon volume to symptoms and weight loss. In addition to IGBs, several other promising therapies have continued to evolve. Endoscopic sleeve gastroplasty (ESG) is a promising gastric restriction technique that has efficacy and durability. POSE is a gastric plication technique that is available in Europe and in clinical trials in the USA. Aspiration therapy is a novel approach to weight loss that requires patient compliance but can be very effective and used long term.

Summary

EBTs are an evolving effective and safe approach for patients who do not qualify for or do not want bariatric surgery. There are multiple EBTs currently FDA approved as well as prospective endoscopic therapies in clinical trials that appear promising.

•• Thompson CC, Abu Dayyeh BK, Kushner R, Sullivan S, Schorr AB, Amaro A, et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol. 2017;112(3):447–57. https://doi.org/10.1038/ajg.2016.500 This is the first, randomized, controlled trial evaluating aspiration therapy.CrossRefPubMed

Ponce J, Woodman G, Swain J, Wilson E, English W, Ikramuddin S, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11(4):874–81. https://doi.org/10.1016/j.soard.2014.12.006.CrossRefPubMed

Farina MG, Baratta R, Nigro A, Vinciguerra F, Puglisi C, Schembri R, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg. 2012;22(4):565–71. https://doi.org/10.1007/s11695-011-0514-y.CrossRefPubMed

Force ABET, Sullivan S, Kumar N, Edmundowicz SA, Abu Dayyeh BK, Jonnalagadda SS, et al. ASGE position statement on endoscopic bariatric therapies in clinical practice. Gastrointest Endosc. 2015;82(5):767–72. https://doi.org/10.1016/j.gie.2015.06.038.CrossRef

Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149(3):275–87. https://doi.org/10.1001/jamasurg.2013.3654.CrossRefPubMedPubMedCentral

US Food and Drug Administration. Summary of safety and effectiveness data (SSED) ReShape Integrated Dual Balloon System. 2015. https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140012b.pdf. Accessed 2 Jan 2019.

Agnihotri A, Xie A, Bartalos C, Kushnir V, Islam S, Islam E, et al. Real-world safety and efficacy of fluid-filled dual intragastric balloon for weight loss. Clin Gastroenterol Hepatol. 2018;16(7):1081–8 e1. https://doi.org/10.1016/j.cgh.2018.02.026.CrossRefPubMed

US Food and Drug Administration. Summary of safety and effectiveness data (SSED) ORBERA Intragastric Balloon System. 2015. https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140008b.pdf. Accessed 2 Jan 2019.

Courcoulas A, Abu Dayyeh BK, Eaton L, Robinson J, Woodman G, Fusco M, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes. 2017;41(3):427–33. https://doi.org/10.1038/ijo.2016.229.CrossRef

10.

Vargas EJ, Pesta CM, Bali A, Ibegbu E, Bazerbachi F, Moore RL, et al. Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population. Clin Gastroenterol Hepatol. 2018;16(7):1073–80 e1. https://doi.org/10.1016/j.cgh.2018.01.046.CrossRefPubMedPubMedCentral

11.

•• Sullivan S, Swain J, Woodman G, Edmundowicz S, Hassanein T, Shayani V, et al. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surg Obes Relat Dis. 2018;14(12):1876–89. https://doi.org/10.1016/j.soard.2018.09.486 This is the first randomized sham-controlled trial of a swallowable gas-filled balloon.CrossRefPubMed

12.

• Moore RL, Seger MV, Garber SM, Smith AB, Nguyen RT, Shieh MK, et al. Clinical safety and effectiveness of a swallowable gas-filled intragastric balloon system for weight loss: consecutively treated patients in the initial year of US commercialization. Surg Obes Relat Dis. 2018. https://doi.org/10.1016/j.soard.2018.12.007 This report analyzes patients in a prospective registry of patients in all practice types who underwent Obalon placement in its first year of availability in the USA.CrossRefPubMed

13.

•• Machytka E, Gaur S, Chuttani R, Bojkova M, Kupka T, Buzga M, et al. Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study. Endoscopy. 2017;49(2):154–60. https://doi.org/10.1055/s-0042-119296 This is the first observational, multicenter trial of the Elipse IGB.CrossRefPubMed

14.

Genco A, Ernesti I, Ienca R, Casella G, Mariani S, Francomano D, et al. Safety and efficacy of a new swallowable intragastric balloon not needing endoscopy: early Italian experience. Obes Surg. 2018;28(2):405–9. https://doi.org/10.1007/s11695-017-2877-1.CrossRefPubMed

15.

Alsabah S, Al Haddad E, Ekrouf S, Almulla A, Al-Subaie S, Al Kendari M. The safety and efficacy of the procedureless intragastric balloon. Surg Obes Relat Dis. 2018;14(3):311–7. https://doi.org/10.1016/j.soard.2017.12.001.CrossRefPubMed

16.

Raftopoulos I, Giannakou A. The Elipse Balloon, a swallowable gastric balloon for weight loss not requiring sedation, anesthesia or endoscopy: a pilot study with 12-month outcomes. Surg Obes Relat Dis. 2017;13(7):1174–82. https://doi.org/10.1016/j.soard.2017.02.016.CrossRefPubMed

17.

Usuy E, Brooks J. Response rates with the Spatz3 adjustable balloon. Obes Surg. 2018;28(5):1271–6. https://doi.org/10.1007/s11695-017-2994-x.CrossRefPubMed

18.

Gomez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity (Silver Spring). 2016;24(9):1849–53. https://doi.org/10.1002/oby.21555.CrossRef

19.

Apollo Endosurgery. News about ReShape ready. 2018. https://www.orbera.com/reshape/. Accessed 26 Dec 2018.

20.

Force ABET, Committee AT, Abu Dayyeh BK, Kumar N, Edmundowicz SA, Jonnalagadda S, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–38 e5. https://doi.org/10.1016/j.gie.2015.03.1964.CrossRef

21.

Abu Dayyeh BK, Eaton LL, Woodman G, Fusco M, Shayani F, Billy HT, et al. 444 a randomized, multi-center study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program, in comparison with a behavioral modification program alone in the weight management of obese subjects. Gastrointest Endosc. 2015;81(5):AB147.CrossRef

22.

Ashrafian H, Monnich M, Braby TS, Smellie J, Bonanomi G, Efthimiou E. Intragastric balloon outcomes in super-obesity: a 16-year city center hospital series. Surg Obes Relat Dis. 2018;14(11):1691–9. https://doi.org/10.1016/j.soard.2018.07.010.CrossRefPubMed

23.

US Food and Drug Administration. Summary of safety and effectiveness data (SSED) Obalon Balloon System. 2016. https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160001b.pdf. Accessed 2 Jan 2019.

24.

Mion F, Ibrahim M, Marjoux S, Ponchon T, Dugardeyn S, Roman S, et al. Swallowable Obalon(R) gastric balloons as an aid for weight loss: a pilot feasibility study. Obes Surg. 2013;23(5):730–3. https://doi.org/10.1007/s11695-013-0927-x.CrossRefPubMed

25.

US Food and Drug Administration. Premarket approval (PMA): Obalon touch inflation system. 2018. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160001S007. Accessed 3 Jan 2019.

26.

US Food and Drug Administration. Premarket approval (PMA): Obalon balloon system with navigation touch. 2018. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160001S020. Accessed 3 Jan 2019.

27.

De Peppo F, Caccamo R, Adorisio O, Ceriati E, Marchetti P, Contursi A, et al. The Obalon swallowable intragastric balloon in pediatric and adolescent morbid obesity. Endosc Int Open. 2017;5(1):E59–63. https://doi.org/10.1055/s-0042-120413.CrossRefPubMedPubMedCentral

28.

Machytka E, Chuttani R, Bojkova M, Kupka T, Buzga M, Stecco K, et al. Elipse, a procedureless gastric balloon for weight loss: a proof-of-concept pilot study. Obes Surg. 2016;26(3):512–6. https://doi.org/10.1007/s11695-015-1783-7.CrossRefPubMed

29.

Brooks J, Srivastava ED, Mathus-Vliegen EM. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg. 2014;24(5):813–9. https://doi.org/10.1007/s11695-014-1176-3.CrossRefPubMed

30.

Machytka E, Klvana P, Kornbluth A, Peikin S, Mathus-Vliegen LE, Gostout C, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg. 2011;21(10):1499–507. https://doi.org/10.1007/s11695-011-0424-z.CrossRefPubMedPubMedCentral

31.

Trang J, Lee SS, Miller A, Cruz Pico CX, Postoev A, Ibikunle I, et al. Incidence of nausea and vomiting after intragastric balloon placement in bariatric patients - a systematic review and meta-analysis. Int J Surg. 2018;57:22–9. https://doi.org/10.1016/j.ijsu.2018.06.038.CrossRefPubMed

32.

Maisel W. The FDA alerts health care providers about potential risks with liquid-filled intragastric balloons. 2017. https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm540655.htm. Accessed 16 Feb 2019.

33.

US Food and Drug Administration. Update: potential risks with liquid-filled intragastric balloons -- letter to health care providers. 2017. https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm570707.htm. Accessed 16 Feb 2019.

34.

US Food and Drug Administration. Update: potential risks with liquid-filled intragastric balloons - letter to health care providers. 2018. https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm609597.htm. Accessed 16 Feb 2019.

35.

US Food and Drug Administration. MAUDE - manufacturer and user facility device experience. 2019. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm. Accessed 10 Mar 2019.

36.

Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc. 2013;78(3):530–5. https://doi.org/10.1016/j.gie.2013.04.197.CrossRefPubMed

37.

Kumar N, Abu Dayyeh BK, Lopez-Nava Breviere G, Galvao Neto MP, Sahdala NP, Shaikh SN, et al. Endoscopic sutured gastroplasty: procedure evolution from first-in-man cases through current technique. Surg Endosc. 2018;32(4):2159–64. https://doi.org/10.1007/s00464-017-5869-2.CrossRefPubMed

38.

Abu Dayyeh BK, Acosta A, Camilleri M, Mundi MS, Rajan E, Topazian MD, et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol. 2017;15(1):37–43 e1. https://doi.org/10.1016/j.cgh.2015.12.030.CrossRefPubMed

39.

Sharaiha RZ, Kumta NA, Saumoy M, Desai AP, Sarkisian AM, Benevenuto A, et al. Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients. Clin Gastroenterol Hepatol. 2017;15(4):504–10. https://doi.org/10.1016/j.cgh.2016.12.012.CrossRefPubMed

40.

• Lopez-Nava G, Sharaiha RZ, Vargas EJ, Bazerbachi F, Manoel GN, Bautista-Castano I, et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg. 2017;27(10):2649–55. https://doi.org/10.1007/s11695-017-2693-7 This study demonstrated that 6-month weight loss is a significant predictor of long-term weight loss in ESG.CrossRefPubMed

41.

Sartoretto A, Sui Z, Hill C, Dunlap M, Rivera AR, Khashab MA, et al. Endoscopic sleeve gastroplasty (ESG) is a reproducible and effective endoscopic bariatric therapy suitable for widespread clinical adoption: a large, international multicenter study. Obes Surg. 2018;28(7):1812–21. https://doi.org/10.1007/s11695-018-3135-x.CrossRefPubMed

42.

• Alqahtani A, Al-Darwish A, Mahmoud AE, Alqahtani YA, Elahmedi M. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest Endosc. 2018. https://doi.org/10.1016/j.gie.2018.12.012 This prospective, single-center study is the largest study to-date evaluating patients undergoing ESG.CrossRefPubMed

43.

Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology. 2017;152(7):1791–801. https://doi.org/10.1053/j.gastro.2017.01.044.CrossRefPubMed

44.

Espinos JC, Turro R, Moragas G, Bronstone A, Buchwald JN, Mearin F, et al. Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure. Obes Surg. 2016;26(5):1081–9. https://doi.org/10.1007/s11695-015-1863-8.CrossRefPubMed

45.

Espinos JC, Turro R, Mata A, Cruz M, da Costa M, Villa V, et al. Early experience with the incisionless operating platform (IOP) for the treatment of obesity : the primary obesity surgery endolumenal (POSE) procedure. Obes Surg. 2013;23(9):1375–83. https://doi.org/10.1007/s11695-013-0937-8.CrossRefPubMed

46.

•• Sullivan S, Swain JM, Woodman G, Antonetti M, De L, Cruz-Munoz N, et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial. Obesity (Silver Spring). 2017;25(2):294–301. https://doi.org/10.1002/oby.21702 This is the first multicenter, randomized sham-controlled trial evaluating POSE.CrossRef

47.

Miller K, Turro R, Greve JW, Bakker CM, Buchwald JN, Espinos JC. MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose (SM) vs. medical therapy. Obes Surg. 2017;27(2):310–22. https://doi.org/10.1007/s11695-016-2295-9.CrossRefPubMed

48.

Lopez-Nava G, Bautista-Castano I, Jimenez A, de Grado T, Fernandez-Corbelle JP. The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis. 2015;11(4):861–5. https://doi.org/10.1016/j.soard.2014.09.026.CrossRefPubMed

49.

US Food and Drug Administration. Summary of safety and effectiveness data (SSED) AspireAssist. 2016. https://www.accessdata.fda.gov/cdrh_docs/pdf15/p150024b.pdf. Accessedd 16 Feb 2019.

50.

Nystrom M, Machytka E, Noren E, Testoni PA, Janssen I, Turro Homedes J, et al. Aspiration therapy as a tool to treat obesity: 1- to 4-year results in a 201-patient multi-center post-market European registry study. Obes Surg. 2018;28(7):1860–8. https://doi.org/10.1007/s11695-017-3096-5.CrossRefPubMedPubMedCentral

51.

Sullivan S, Stein R, Jonnalagadda S, Mullady D, Edmundowicz S. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology. 2013;145(6):1245–52 e1-5. https://doi.org/10.1053/j.gastro.2013.08.056.CrossRefPubMed

52.

US Department of Health and Human Services. Health, United States, 2017 With special feature on mortality. 2017. https://www.cdc.gov/nchs/data/hus/hus17.pdf#053. Accessed 4 Jan 2019.

53.

Organisation for Economic Co-operation and Development. Obesity update 2017. 2017. https://www.oecd.org/els/health-systems/Obesity-Update-2017.pdf. Accessed 4 Jan 2019.

54.

Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ. 2012;31(1):219–30. https://doi.org/10.1016/j.jhealeco.2011.10.003.CrossRefPubMed

55.

Dumon KR, Murayama KM. Bariatric surgery outcomes. Surg Clin North Am. 2011;91(6):1313–38, x. https://doi.org/10.1016/j.suc.2011.08.014.CrossRefPubMed

Title: Endoscopic Bariatric Therapies: Intragastric Balloons, Tissue Apposition, and Aspiration Therapy
Authors: Joshua A. Turkeltaub, MD
Steven A. Edmundowicz, MD
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Obesity
Obesity
Foreign Body Aspiration
Foreign Body Aspiration
Aspiration
Published in: Current Treatment Options in Gastroenterology / Issue 2/2019
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-019-00232-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Endoscopic Bariatric Therapies: Intragastric Balloons, Tissue Apposition, and Aspiration Therapy

Abstract

Purpose of review

Recent findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2019

Contemporary Epidemiology of Cirrhosis

Albumin in Cirrhosis: More Than a Colloid

Colorectal Cancer Screening and Surveillance Colonoscopy in Older Adults

Updates on Chronic HBV: Current Challenges and Future Goals

Update in Surveillance Recommendations in Individuals With Conventional Adenomas

2007–2019: a “Third”-Space Odyssey in the Endoscopic Management of Gastrointestinal Tract Diseases

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page